Business
AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate
SEATTLE & HEIDELBERG, Germany, July 29, 2025--AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO’s Heidelberg facility.
About this update from Valneva Se
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2050,"height":571,"url":"https://media.zenfs.com/en/business-wire.com/2e41ce014e7490b7b3b6663edf9a497c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MOK9h31V3p8y8vrqWvQjfA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2e41ce014e7490b7b3b6663edf9a497c","width":960,"height":267},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XqvxjOxhas6bkGdRBvLEzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02Njg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2e41ce014e7490b7b3b6663edf9a497c","width":1200,"height":334}},"lazy":false},{"type":"text","content":"SEATTLE & HEIDELBERG, Germany, July 29, 2025--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO’s Heidelberg facility.","length":378,"tagName":"p"},{"type":"text","content":"Valneva exclusively licensed the vaccine candidate from LimmaTech Biologics AG, which previously worked with AGC Biologics to establish GMP-compliant manufacturing and quality control of the vaccine’s complex protein-polysaccharide conjugates for first-in-human studies. The objective of the new partnership with Valneva is to establish phase II supply relying on the ability of AGC Biologics’ Heidelberg site to guide complex molecules through clinical stages. Valneva and LimmaTech announced the launch of a Phase 2 infant study in April, and a Phase 2b Human Challenge Study (CHIM) in November 2024.","length":602,"tagName":"p"},{"type":"text","content":"Shigellosis is the second leading cause of fatal diarrheal disease worldwide, strongly contributing to pediatric morbidity and mortality. It is estimated that up to 165 million infections are due to Shigella, of which 62.3 million occur in children younger than five years. Developing an effective vaccine to prevent this deadly disease is a public health imperative for many areas of the world.","length":395,"tagName":"p"},{"type":"text","content":""Our site's unique ability to handle complex molecules and multi-valent as...